英國BBI Solutions成立于1986年，是體外診斷試劑領(lǐng)域專(zhuān)業(yè)制造商，為生命科學(xué)行業(yè)和體外診斷行業(yè)提供診斷試劑原料、標準品及技術(shù)服務(wù)，現已從一家小型專(zhuān)業(yè)公司成長(cháng)為業(yè)務(wù)生產(chǎn)基地橫跨三個(gè)國家的大型企業(yè)。

BBI Solutions主要經(jīng)營(yíng)產(chǎn)品包括人源抗原、抗體、血清、血漿、臨床化學(xué)酶和黃金納米顆粒。

BBI Solutions人源蛋白

BBI Solutions人源蛋白是從人類(lèi)血清或組織中純化所得，符合倫理法規要求；重組蛋白使用大腸桿菌和畢赤酵母表達系統，在專(zhuān)業(yè)的實(shí)驗室中進(jìn)行生產(chǎn)；去血清產(chǎn)品，可顯著(zhù)消除基質(zhì)效應，提高生物標志物的檢測效果，并產(chǎn)生可重復的標準曲線(xiàn)。

CEA Antigen (recombinant) 癌胚抗原  貨號：P824-3

CEA was first identified in human colon carcinoma tissue extracts and is known to play a critical role as a ligand in cancer dissemination. Elevated serum CEA is found in 17～47% of colorectal cancer patients. CEA was originally thought to be a specific marker for colon cancer but levels may also be raised in gastric, pancreatic, lung, breast and medullary thyroid carcinomas, as well as some non-neoplastic conditions such as inflammation, pancreatitis, ulcerative colitis, cirrhosis, COPD, Crohn's disease, hypothyroidism and in smokers. For this reason, it is not useful as a general cancer screening tool, but can be useful in evaluating the response to cancer treatment, to monitor metastasis of colorectal cancer to the liver and to indicate recurrence. Elevated CEA levels should return to normal after successful surgical removal of the tumour and can be used in follow up, especially of colorectal cancers. CEA elevation is known to be affected by multiple factors and it varies inversely with tumor grade; well-differentiated tumours secrete more CEA.

產(chǎn)品詳情：https://www.bbisolutions.com/cn/product/carcinoembryonic-antigen-cea

希凱生物是英國BBI Solutions授權代理商，更多產(chǎn)品信息，歡迎直接與我們聯(lián)系~